The IMF Advocacy program trains and supports concerned individuals to advocate on health issues that affect the myeloma community. Working at both the U.S. state and federal level, the IMF supports legislation that betters the lives of multiple myeloma patients nationwide.
We need YOUR help to get this information to community oncologists.
Subscribe to our advocacy e-mail list for the latest happenings and news.
Emma Hatcher holds the position of Global Vice President for Patient Engagement & Advocacy, leveraging her extensive 20+ years of healthcare experience. Notably, she spent 15 years in the pharmaceutical industry with a focus on rare disease treatments in global markets. Emma's expertise was built by working at the intersection of health policy, patient advocacy, and strategic planning, a background built through roles spanning industry, consulting, and trade associations. Emma holds a master's degree in public health with a policy concentration from Brown University, and a Bachelor of Sciences from the University of Rhode Island. Emma resides in the Washington D.C. area with her husband and two children.
Danielle Doheny joined IMF after a six-year career on Capitol Hill where she worked as an adviser to two members of Congress. As a Congressional staffer, Danielle’s primary focus was on healthcare and issues related to energy, the environment, science, and technology. In her role with the IMF, she advocates on behalf of the multiple myeloma community to the executive and legislative branches of the federal government. Danielle’s father is a multiple myeloma patient, and she has a unique passion for her work on behalf of patients and their families. Danielle graduated cum laude from Thiel College with a Bachelor of Arts degree in History.
Dr. Mimi Choon-Quinones joined the IMF in 2018, bringing with her more than 20 years of experience in the pharmaceutical industry, her strategic leadership in 88+ countries focusing on Medical and Clinical Operations. Mimi was raised in the US, has lived and worked in Canada, and currently resides in Switzerland. She is working diligently with the i2TEAMM initiative to gain approval of MRD as a surrogate endpoint in myeloma in Europe, through efforts with the European Medicines Authority (EMA). Additionally Mimi will focus her efforts on IMF research initiatives and policy issues related to access to care and therapy in Europe.
Serdar joined the IMF in September 2018 with seven years of experience in the non-profit sector, specializing in corporate communications and development. For the prior four years, he was part of the business development team at the Educational Volunteers Foundation of Turkey (TEGV). Earlier in his career, Serdar spent more than 15 years working with global corporations. He is the co-founder of Living With Myeloma Initiative and Cancer Survivors Association that has organized patient and family seminars in several cities in Turkey. Serdar is also a journalist, translator, editor, content provider, and musician.
Give Now or Give Monthly. Choose a way that works for you.